Tuesday January 13, 2026  |  11am PT
FDA Outlook in a New Year

FDA has been in a state of flux, with a slew of new Commissioner priorities – many of which have not been detailed in regulatory guidance – with proposals, stakeholder input, and finalization. We will discuss the Commissioner’s Voucher (CNPV) program, MFN, and new pathways concerning ultra orphan, minimized clinical trial requirements, and other initiatives. We will provide guidance to companies and stakeholders interacting with FDA, as we look ahead to a new year.

Wednesday January 14, 2026  |  1:30pm PT
Unlocking Investment for Women’s Health Innovation

Over the past 12 months, there have been several new initiatives for funding women’s health, which has further fueled an ongoing trend of innovation and investment. Hear from these fund managers and what is driving their enthusiasm – including health policy in DC – on why now is time for increasing investment in women’s health.